How to use and operate Teritusumab/Telica

Teritusumab (Teclistamab-cqyv) is a bispecific antibody drug administered by subcutaneous injection. Its use is relatively standardized and must be performed by medical personnel in experienced medical institutions. The drug adopts an ascending dose regimen to reduce the risk of early immune response in multiple myeloma (MM) and improve the overall drug safety.

In terms of route of administration, teritusumab is administered by subcutaneous injection, often in the abdomen, thighs, or other areas with abundant subcutaneous fat. Injection sites often need to be rotated to reduce local irritation and skin reactions.

1. In the initial phase, all patients need to receive an ascending dose regimen. On the first day, an incremental dose of 1 is given, which is 0.06mg/kg, which is the lowest starting dose; on the fourth day, an incremental dose of 2 is given, which is 0.3mg/kg; on the seventh day, the first therapeutic dose is given, which is 1.5mg/kg;

2. After completing the first treatment dose, the patient enters the routine maintenance dosing phase. The standard protocol is subcutaneous injection once a week, and the subsequent treatment dose is fixed at 1.5 mg/kg, which is continued until disease progression or unacceptable toxicity.

3. For patients who achieve and maintain complete remission or better efficacy for at least6 months, the dosing frequency can be adjusted after the doctor’s evaluation. The dosing frequency can be reduced to once every two weeks, and the dose can still be maintained at 1.5 mg/kg; this regimen can help reduce the burden of long-term treatment and improve the quality of life

In terms of safety management, patients generally require hospitalization for at least 48 hours after all doses in the escalating dose phase. This measure is mainly used to promptly identify and treat possible immune-related reactions. Increasing dose 2 can be administered within 2 to 4 days after increasing dose 1, and can be extended to 7 days if necessary; the first treatment dose can also be administered within 2 to 4 days after the second increasing dose, and is allowed to be adjusted within 7 days so that treatment can be continued after symptoms are relieved.

In general, the use of teritusumab emphasizes gradual progress, close monitoring and individualized adjustment. Standardized operation is the key to ensuring efficacy and safety.

Keyword tag: Teritusumab Usage and Dosage Telivac Teclistamab Subcutaneous Injection Increasing Dose Dosage Scheme Multiple Myeloma

Reference materials:https://www.tecvayli.com/